MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma - PubMed (original) (raw)
Comparative Study
. 2005 Mar 1;174(5):3080-6.
doi: 10.4049/jimmunol.174.5.3080.
Jennifer Pressley, Courtney Garbee, Sarah Hibbitts, Cheryl Murphy, Galina Yamshchikov, Gina R Petroni, Eric A Bissonette, Patrice Y Neese, William W Grosh, Priscilla Merrill, Robyn Fink, Elizabeth M H Woodson, Catherine J Wiernasz, James W Patterson, Craig L Slingluff Jr
Affiliations
- PMID: 15728523
- DOI: 10.4049/jimmunol.174.5.3080
Comparative Study
MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma
Kimberly A Chianese-Bullock et al. J Immunol. 2005.
Abstract
Twelve peptides derived from melanocyte differentiation proteins and cancer-testis Ags were combined and administered in a single mixture to patients with resected stage IIB, III, or IV melanoma. Five of the 12 peptides included in this mixture had not previously been evaluated for their immunogenicity in vivo following vaccination. We report in this study that at least three of these five peptides (MAGE-A1(96-104), MAGE-A10(254-262), and gp100(614-622)) are immunogenic when administered with GM-CSF in Montanide ISA-51 adjuvant. T cells secreting IFN-gamma in response to peptide-pulsed target cells were detected in peripheral blood and in the sentinel immunized node, the node draining a vaccine site, after three weekly injections. The magnitude of response typically reached a maximum after two vaccines, and though sometimes diminished thereafter, those responses typically were still detectable 6 wks after the last vaccines. Most importantly, tumor cell lines expressing the appropriate HLA-A restriction element and MAGE-A1, MAGE-A10, or gp100 proteins were lysed by corresponding CTL. This report supports the continued use of the MAGE-A1(96-104), MAGE-A10(254-262), and gp100(614-622) epitopes in peptide-based melanoma vaccines and thus expands the list of immunogenic peptide Ags available for human use. Cancer-testis Ags are expressed in multiple types of cancer; thus the MAGE-A1(96-104) and MAGE-A10(254-262) peptides may be considered for inclusion in vaccines against cancers of other histologic types, in addition to melanoma.
Similar articles
- Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, Neese PY, Grosh WW, Chianese-Bullock KA, Woodson EM, Wiernasz CJ, Merrill P, Gibson J, Ross M, Engelhard VH. Slingluff CL Jr, et al. J Clin Oncol. 2003 Nov 1;21(21):4016-26. doi: 10.1200/JCO.2003.10.005. J Clin Oncol. 2003. PMID: 14581425 Clinical Trial. - Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Markovic SN, Suman VJ, Ingle JN, Kaur JS, Pitot HC, Loprinzi CL, Rao RD, Creagan ET, Pittelkow MR, Allred JB, Nevala WK, Celis E. Markovic SN, et al. Am J Clin Oncol. 2006 Aug;29(4):352-60. doi: 10.1097/01.coc.0000217877.78473.a4. Am J Clin Oncol. 2006. PMID: 16891861 Clinical Trial. - Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.
Slingluff CL Jr, Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH, Kittlesen D, Deacon D, Hibbitts S, Grosh WW, Petroni G, Cohen R, Wiernasz C, Patterson JW, Conway BP, Ross WG. Slingluff CL Jr, et al. Clin Cancer Res. 2001 Oct;7(10):3012-24. Clin Cancer Res. 2001. PMID: 11595689 Clinical Trial. - Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines.
Chiang CL, Kandalaft LE, Coukos G. Chiang CL, et al. Int Rev Immunol. 2011 Apr-Jun;30(2-3):150-82. doi: 10.3109/08830185.2011.572210. Int Rev Immunol. 2011. PMID: 21557641 Review. - Melanoma-associated antigens recognized by cytotoxic T lymphocytes.
Kirkin AF, Dzhandzhugazyan K, Zeuthen J. Kirkin AF, et al. APMIS. 1998 Jul;106(7):665-79. doi: 10.1111/j.1699-0463.1998.tb00210.x. APMIS. 1998. PMID: 9740504 Review.
Cited by
- An Engineered M13 Filamentous Nanoparticle as an Antigen Carrier for a Malignant Melanoma Immunotherapeutic Strategy.
Brišar N, Šuster K, Brezar SK, Vidmar R, Fonović M, Cör A. Brišar N, et al. Viruses. 2024 Feb 1;16(2):232. doi: 10.3390/v16020232. Viruses. 2024. PMID: 38400008 Free PMC article. - Progress towards Adjuvant Development: Focus on Antiviral Therapy.
Brai A, Poggialini F, Pasqualini C, Trivisani CI, Vagaggini C, Dreassi E. Brai A, et al. Int J Mol Sci. 2023 May 25;24(11):9225. doi: 10.3390/ijms24119225. Int J Mol Sci. 2023. PMID: 37298177 Free PMC article. Review. - Gene-based cancer-testis antigens as prognostic indicators in hepatocellular carcinoma.
Xu Y, Xu X, Ni X, Pan J, Chen M, Lin Y, Zhao Z, Zhang L, Ge N, Song G, Zhang J. Xu Y, et al. Heliyon. 2023 Mar 6;9(3):e13269. doi: 10.1016/j.heliyon.2023.e13269. eCollection 2023 Mar. Heliyon. 2023. PMID: 36950598 Free PMC article. - Identification of potential biomarkers in cancer testis antigens for glioblastoma.
Li F, Liu C, Nong W, Lin L, Ge Y, Luo B, Xiao S, Zhang Q, Xie X. Li F, et al. Am J Transl Res. 2023 Feb 15;15(2):799-816. eCollection 2023. Am J Transl Res. 2023. PMID: 36915736 Free PMC article. - Intratumoral IFN-γ or topical TLR7 agonist promotes infiltration of melanoma metastases by T lymphocytes expanded in the blood after cancer vaccine.
Tran CA, Lynch KT, Meneveau MO, Katyal P, Olson WC, Slingluff CL Jr. Tran CA, et al. J Immunother Cancer. 2023 Feb;11(2):e005952. doi: 10.1136/jitc-2022-005952. J Immunother Cancer. 2023. PMID: 36746511 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials